Limited Efficacy of Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients with Rare RAS Variants: Analysis of the C-CAT Database Article Swipe
Shuhei Suzuki
,
Yosuke Saito
,
Koki Saito
,
Yuta Yamada
,
Koshi Takahashi
,
Ryosuke Kumanishi
,
Tadahisa Fukui
,
Takashi Yoshioka
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.3390/cimb46120869
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.3390/cimb46120869
Epidermal growth factor receptor (EGFR) inhibition is crucial in treating RAS wild-type metastatic colorectal cancer, yet current testing methods may miss rare RAS variants affecting treatment efficacy. We analyzed 4122 colorectal cancer patients receiving anti-EGFR antibodies from the Center for Cancer Genomics and Advanced Therapeutics database, identifying 54 patients (1.3%) with rare RAS variants undetectable by standard testing. These patients showed significantly lower response rates to anti-EGFR therapy (28.3%) compared to RAS wild-type cases (44.6%, p = 0.003). Disease control rates were also lower in rare variant cases (60.9%) versus wild-type cases (80.0%). Most common rare variants included KRAS Q22K, A59E, and A11_G12insGA. Comprehensive genomic profiling revealed additional alterations in TP53 (90.7%), APC (87.0%), and non-V600E BRAF mutations (25.9%). Our findings suggest that rare RAS variants predict poor anti-EGFR therapy response, highlighting the potential benefit of comprehensive genomic profiling before treatment initiation. This study provides real-world evidence supporting the clinical relevance of rare RAS variants in treatment decision-making for colorectal cancer. Future studies should focus on developing cost-effective comprehensive testing strategies and evaluating alternative treatment approaches for patients with rare RAS variants.
Related Topics
Concepts
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.3390/cimb46120869
- https://www.mdpi.com/1467-3045/46/12/869/pdf?version=1734938882
- OA Status
- gold
- Cited By
- 3
- References
- 16
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4405757359
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4405757359Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3390/cimb46120869Digital Object Identifier
- Title
-
Limited Efficacy of Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients with Rare RAS Variants: Analysis of the C-CAT DatabaseWork title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-12-23Full publication date if available
- Authors
-
Shuhei Suzuki, Yosuke Saito, Koki Saito, Yuta Yamada, Koshi Takahashi, Ryosuke Kumanishi, Tadahisa Fukui, Takashi YoshiokaList of authors in order
- Landing page
-
https://doi.org/10.3390/cimb46120869Publisher landing page
- PDF URL
-
https://www.mdpi.com/1467-3045/46/12/869/pdf?version=1734938882Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.mdpi.com/1467-3045/46/12/869/pdf?version=1734938882Direct OA link when available
- Concepts
-
KRAS, Panitumumab, Colorectal cancer, Medicine, Epidermal growth factor receptor, Internal medicine, Oncology, EGFR inhibitors, Personalized medicine, Targeted therapy, Cancer, Cancer research, Database, Bioinformatics, Biology, Computer scienceTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
3Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 3Per-year citation counts (last 5 years)
- References (count)
-
16Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4405757359 |
|---|---|
| doi | https://doi.org/10.3390/cimb46120869 |
| ids.doi | https://doi.org/10.3390/cimb46120869 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/39727997 |
| ids.openalex | https://openalex.org/W4405757359 |
| fwci | 1.61324022 |
| type | review |
| title | Limited Efficacy of Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients with Rare RAS Variants: Analysis of the C-CAT Database |
| biblio.issue | 12 |
| biblio.volume | 46 |
| biblio.last_page | 14486 |
| biblio.first_page | 14476 |
| topics[0].id | https://openalex.org/T11067 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Colorectal Cancer Treatments and Studies |
| topics[1].id | https://openalex.org/T10417 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9926999807357788 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2740 |
| topics[1].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[1].display_name | Lung Cancer Treatments and Mutations |
| topics[2].id | https://openalex.org/T11287 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9918000102043152 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1306 |
| topics[2].subfield.display_name | Cancer Research |
| topics[2].display_name | Cancer Genomics and Diagnostics |
| is_xpac | False |
| apc_list.value | 1800 |
| apc_list.currency | CHF |
| apc_list.value_usd | 1949 |
| apc_paid.value | 1800 |
| apc_paid.currency | CHF |
| apc_paid.value_usd | 1949 |
| concepts[0].id | https://openalex.org/C2781187634 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9133115410804749 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q20969980 |
| concepts[0].display_name | KRAS |
| concepts[1].id | https://openalex.org/C2778332735 |
| concepts[1].level | 5 |
| concepts[1].score | 0.830199122428894 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q417775 |
| concepts[1].display_name | Panitumumab |
| concepts[2].id | https://openalex.org/C526805850 |
| concepts[2].level | 3 |
| concepts[2].score | 0.7560387849807739 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q188874 |
| concepts[2].display_name | Colorectal cancer |
| concepts[3].id | https://openalex.org/C71924100 |
| concepts[3].level | 0 |
| concepts[3].score | 0.6243129968643188 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[3].display_name | Medicine |
| concepts[4].id | https://openalex.org/C2779438470 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5479438900947571 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q424401 |
| concepts[4].display_name | Epidermal growth factor receptor |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.5184863805770874 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| concepts[6].id | https://openalex.org/C143998085 |
| concepts[6].level | 1 |
| concepts[6].score | 0.5157814025878906 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[6].display_name | Oncology |
| concepts[7].id | https://openalex.org/C2777506169 |
| concepts[7].level | 4 |
| concepts[7].score | 0.4440747797489166 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q424401 |
| concepts[7].display_name | EGFR inhibitors |
| concepts[8].id | https://openalex.org/C32220436 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4191637635231018 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2072214 |
| concepts[8].display_name | Personalized medicine |
| concepts[9].id | https://openalex.org/C2781230642 |
| concepts[9].level | 3 |
| concepts[9].score | 0.4160976707935333 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q492646 |
| concepts[9].display_name | Targeted therapy |
| concepts[10].id | https://openalex.org/C121608353 |
| concepts[10].level | 2 |
| concepts[10].score | 0.3695339262485504 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[10].display_name | Cancer |
| concepts[11].id | https://openalex.org/C502942594 |
| concepts[11].level | 1 |
| concepts[11].score | 0.3621213436126709 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[11].display_name | Cancer research |
| concepts[12].id | https://openalex.org/C77088390 |
| concepts[12].level | 1 |
| concepts[12].score | 0.340513676404953 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q8513 |
| concepts[12].display_name | Database |
| concepts[13].id | https://openalex.org/C60644358 |
| concepts[13].level | 1 |
| concepts[13].score | 0.2977703809738159 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q128570 |
| concepts[13].display_name | Bioinformatics |
| concepts[14].id | https://openalex.org/C86803240 |
| concepts[14].level | 0 |
| concepts[14].score | 0.23142537474632263 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[14].display_name | Biology |
| concepts[15].id | https://openalex.org/C41008148 |
| concepts[15].level | 0 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q21198 |
| concepts[15].display_name | Computer science |
| keywords[0].id | https://openalex.org/keywords/kras |
| keywords[0].score | 0.9133115410804749 |
| keywords[0].display_name | KRAS |
| keywords[1].id | https://openalex.org/keywords/panitumumab |
| keywords[1].score | 0.830199122428894 |
| keywords[1].display_name | Panitumumab |
| keywords[2].id | https://openalex.org/keywords/colorectal-cancer |
| keywords[2].score | 0.7560387849807739 |
| keywords[2].display_name | Colorectal cancer |
| keywords[3].id | https://openalex.org/keywords/medicine |
| keywords[3].score | 0.6243129968643188 |
| keywords[3].display_name | Medicine |
| keywords[4].id | https://openalex.org/keywords/epidermal-growth-factor-receptor |
| keywords[4].score | 0.5479438900947571 |
| keywords[4].display_name | Epidermal growth factor receptor |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.5184863805770874 |
| keywords[5].display_name | Internal medicine |
| keywords[6].id | https://openalex.org/keywords/oncology |
| keywords[6].score | 0.5157814025878906 |
| keywords[6].display_name | Oncology |
| keywords[7].id | https://openalex.org/keywords/egfr-inhibitors |
| keywords[7].score | 0.4440747797489166 |
| keywords[7].display_name | EGFR inhibitors |
| keywords[8].id | https://openalex.org/keywords/personalized-medicine |
| keywords[8].score | 0.4191637635231018 |
| keywords[8].display_name | Personalized medicine |
| keywords[9].id | https://openalex.org/keywords/targeted-therapy |
| keywords[9].score | 0.4160976707935333 |
| keywords[9].display_name | Targeted therapy |
| keywords[10].id | https://openalex.org/keywords/cancer |
| keywords[10].score | 0.3695339262485504 |
| keywords[10].display_name | Cancer |
| keywords[11].id | https://openalex.org/keywords/cancer-research |
| keywords[11].score | 0.3621213436126709 |
| keywords[11].display_name | Cancer research |
| keywords[12].id | https://openalex.org/keywords/database |
| keywords[12].score | 0.340513676404953 |
| keywords[12].display_name | Database |
| keywords[13].id | https://openalex.org/keywords/bioinformatics |
| keywords[13].score | 0.2977703809738159 |
| keywords[13].display_name | Bioinformatics |
| keywords[14].id | https://openalex.org/keywords/biology |
| keywords[14].score | 0.23142537474632263 |
| keywords[14].display_name | Biology |
| language | en |
| locations[0].id | doi:10.3390/cimb46120869 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S62841813 |
| locations[0].source.issn | 1467-3037, 1467-3045 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1467-3037 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Current Issues in Molecular Biology |
| locations[0].source.host_organization | https://openalex.org/P4310311742 |
| locations[0].source.host_organization_name | Caister Academic Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311742 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.mdpi.com/1467-3045/46/12/869/pdf?version=1734938882 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Current Issues in Molecular Biology |
| locations[0].landing_page_url | https://doi.org/10.3390/cimb46120869 |
| locations[1].id | pmid:39727997 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Current issues in molecular biology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/39727997 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:11674416 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Curr Issues Mol Biol |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11674416 |
| locations[3].id | pmh:oai:doaj.org/article:342e3b1ab8db40709f13714d28152c19 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].source.host_organization_lineage | |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Current Issues in Molecular Biology, Vol 46, Iss 12, Pp 14476-14486 (2024) |
| locations[3].landing_page_url | https://doaj.org/article/342e3b1ab8db40709f13714d28152c19 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5114928862 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-1975-0146 |
| authorships[0].author.display_name | Shuhei Suzuki |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I112524849 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Clinical Oncology, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan |
| authorships[0].affiliations[1].institution_ids | https://openalex.org/I112524849 |
| authorships[0].affiliations[1].raw_affiliation_string | Yamagata Hereditary Tumor Research Center, Yamagata University, 1-4-12 Kojirakawa, Yamagata 990-8560, Japan |
| authorships[0].institutions[0].id | https://openalex.org/I112524849 |
| authorships[0].institutions[0].ror | https://ror.org/00xy44n04 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I112524849 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | Yamagata University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Shuhei Suzuki |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Department of Clinical Oncology, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan, Yamagata Hereditary Tumor Research Center, Yamagata University, 1-4-12 Kojirakawa, Yamagata 990-8560, Japan |
| authorships[1].author.id | https://openalex.org/A5103496533 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Yosuke Saito |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210101432 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Gastroenterology, Yamagata City Hospital Saiseikan, 1-2-26 Nanokamachi, Yamagata 990-0042, Japan |
| authorships[1].institutions[0].id | https://openalex.org/I4210101432 |
| authorships[1].institutions[0].ror | https://ror.org/00nf8fy32 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210101432 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Yamagata City Hospital Saiseikan |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Yosuke Saito |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Gastroenterology, Yamagata City Hospital Saiseikan, 1-2-26 Nanokamachi, Yamagata 990-0042, Japan |
| authorships[2].author.id | https://openalex.org/A5108718047 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Koki Saito |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I158929114 |
| authorships[2].affiliations[0].raw_affiliation_string | Graduate School of Medicine, Tokyo Medical University, 6-1-1 Shinjuku, Tokyo 160-8402, Japan |
| authorships[2].institutions[0].id | https://openalex.org/I158929114 |
| authorships[2].institutions[0].ror | https://ror.org/00k5j5c86 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I158929114 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Tokyo Medical University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Koki Saito |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Graduate School of Medicine, Tokyo Medical University, 6-1-1 Shinjuku, Tokyo 160-8402, Japan |
| authorships[3].author.id | https://openalex.org/A5066437271 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-9698-4301 |
| authorships[3].author.display_name | Yuta Yamada |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I112524849 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Clinical Oncology, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan |
| authorships[3].institutions[0].id | https://openalex.org/I112524849 |
| authorships[3].institutions[0].ror | https://ror.org/00xy44n04 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I112524849 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | Yamagata University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Yuta Yamada |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Clinical Oncology, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan |
| authorships[4].author.id | https://openalex.org/A5050931597 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-0087-7905 |
| authorships[4].author.display_name | Koshi Takahashi |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I112524849 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Clinical Oncology, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan |
| authorships[4].institutions[0].id | https://openalex.org/I112524849 |
| authorships[4].institutions[0].ror | https://ror.org/00xy44n04 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I112524849 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | Yamagata University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Koshi Takahashi |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Clinical Oncology, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan |
| authorships[5].author.id | https://openalex.org/A5080416167 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Ryosuke Kumanishi |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I112524849 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Clinical Oncology, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan |
| authorships[5].institutions[0].id | https://openalex.org/I112524849 |
| authorships[5].institutions[0].ror | https://ror.org/00xy44n04 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I112524849 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | Yamagata University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Ryosuke Kumanishi |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Clinical Oncology, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan |
| authorships[6].author.id | https://openalex.org/A5112647661 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Tadahisa Fukui |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I112524849 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Clinical Oncology, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan |
| authorships[6].institutions[0].id | https://openalex.org/I112524849 |
| authorships[6].institutions[0].ror | https://ror.org/00xy44n04 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I112524849 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Yamagata University |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Tadahisa Fukui |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Clinical Oncology, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan |
| authorships[7].author.id | https://openalex.org/A5023481395 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-7709-8278 |
| authorships[7].author.display_name | Takashi Yoshioka |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I112524849 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Clinical Oncology, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan |
| authorships[7].institutions[0].id | https://openalex.org/I112524849 |
| authorships[7].institutions[0].ror | https://ror.org/00xy44n04 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I112524849 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | Yamagata University |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Takashi Yoshioka |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Clinical Oncology, School of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.mdpi.com/1467-3045/46/12/869/pdf?version=1734938882 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Limited Efficacy of Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients with Rare RAS Variants: Analysis of the C-CAT Database |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11067 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Colorectal Cancer Treatments and Studies |
| related_works | https://openalex.org/W2106789440, https://openalex.org/W4380568868, https://openalex.org/W2291261728, https://openalex.org/W2087034984, https://openalex.org/W2095157278, https://openalex.org/W2000493038, https://openalex.org/W2106330098, https://openalex.org/W2792885295, https://openalex.org/W2964448169, https://openalex.org/W2133128087 |
| cited_by_count | 3 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 3 |
| locations_count | 4 |
| best_oa_location.id | doi:10.3390/cimb46120869 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S62841813 |
| best_oa_location.source.issn | 1467-3037, 1467-3045 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1467-3037 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Current Issues in Molecular Biology |
| best_oa_location.source.host_organization | https://openalex.org/P4310311742 |
| best_oa_location.source.host_organization_name | Caister Academic Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311742 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.mdpi.com/1467-3045/46/12/869/pdf?version=1734938882 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Current Issues in Molecular Biology |
| best_oa_location.landing_page_url | https://doi.org/10.3390/cimb46120869 |
| primary_location.id | doi:10.3390/cimb46120869 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S62841813 |
| primary_location.source.issn | 1467-3037, 1467-3045 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1467-3037 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Current Issues in Molecular Biology |
| primary_location.source.host_organization | https://openalex.org/P4310311742 |
| primary_location.source.host_organization_name | Caister Academic Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311742 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.mdpi.com/1467-3045/46/12/869/pdf?version=1734938882 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Current Issues in Molecular Biology |
| primary_location.landing_page_url | https://doi.org/10.3390/cimb46120869 |
| publication_date | 2024-12-23 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W2106789440, https://openalex.org/W2108235590, https://openalex.org/W4366236521, https://openalex.org/W2789300355, https://openalex.org/W2308033649, https://openalex.org/W2995262111, https://openalex.org/W6771499672, https://openalex.org/W4384560914, https://openalex.org/W3167814974, https://openalex.org/W4307861905, https://openalex.org/W4404062963, https://openalex.org/W2606435196, https://openalex.org/W4321749653, https://openalex.org/W4392133480, https://openalex.org/W4317569519, https://openalex.org/W2995567940 |
| referenced_works_count | 16 |
| abstract_inverted_index.= | 76 |
| abstract_inverted_index.p | 75 |
| abstract_inverted_index.54 | 47 |
| abstract_inverted_index.We | 27 |
| abstract_inverted_index.by | 55 |
| abstract_inverted_index.in | 8, 84, 109, 155 |
| abstract_inverted_index.is | 6 |
| abstract_inverted_index.of | 135, 151 |
| abstract_inverted_index.on | 165 |
| abstract_inverted_index.to | 65, 70 |
| abstract_inverted_index.APC | 112 |
| abstract_inverted_index.Our | 119 |
| abstract_inverted_index.RAS | 10, 22, 52, 71, 124, 153, 180 |
| abstract_inverted_index.and | 42, 101, 114, 171 |
| abstract_inverted_index.for | 39, 158, 176 |
| abstract_inverted_index.may | 19 |
| abstract_inverted_index.the | 37, 132, 148 |
| abstract_inverted_index.yet | 15 |
| abstract_inverted_index.4122 | 29 |
| abstract_inverted_index.BRAF | 116 |
| abstract_inverted_index.KRAS | 98 |
| abstract_inverted_index.Most | 93 |
| abstract_inverted_index.TP53 | 110 |
| abstract_inverted_index.This | 142 |
| abstract_inverted_index.also | 82 |
| abstract_inverted_index.from | 36 |
| abstract_inverted_index.miss | 20 |
| abstract_inverted_index.poor | 127 |
| abstract_inverted_index.rare | 21, 51, 85, 95, 123, 152, 179 |
| abstract_inverted_index.that | 122 |
| abstract_inverted_index.were | 81 |
| abstract_inverted_index.with | 50, 178 |
| abstract_inverted_index.A59E, | 100 |
| abstract_inverted_index.Q22K, | 99 |
| abstract_inverted_index.These | 58 |
| abstract_inverted_index.cases | 73, 87, 91 |
| abstract_inverted_index.focus | 164 |
| abstract_inverted_index.lower | 62, 83 |
| abstract_inverted_index.rates | 64, 80 |
| abstract_inverted_index.study | 143 |
| abstract_inverted_index.(1.3%) | 49 |
| abstract_inverted_index.(EGFR) | 4 |
| abstract_inverted_index.Cancer | 40 |
| abstract_inverted_index.Center | 38 |
| abstract_inverted_index.Future | 161 |
| abstract_inverted_index.before | 139 |
| abstract_inverted_index.cancer | 31 |
| abstract_inverted_index.common | 94 |
| abstract_inverted_index.factor | 2 |
| abstract_inverted_index.growth | 1 |
| abstract_inverted_index.should | 163 |
| abstract_inverted_index.showed | 60 |
| abstract_inverted_index.versus | 89 |
| abstract_inverted_index.(28.3%) | 68 |
| abstract_inverted_index.(44.6%, | 74 |
| abstract_inverted_index.(60.9%) | 88 |
| abstract_inverted_index.0.003). | 77 |
| abstract_inverted_index.Disease | 78 |
| abstract_inverted_index.benefit | 134 |
| abstract_inverted_index.cancer, | 14 |
| abstract_inverted_index.cancer. | 160 |
| abstract_inverted_index.control | 79 |
| abstract_inverted_index.crucial | 7 |
| abstract_inverted_index.current | 16 |
| abstract_inverted_index.genomic | 104, 137 |
| abstract_inverted_index.methods | 18 |
| abstract_inverted_index.predict | 126 |
| abstract_inverted_index.studies | 162 |
| abstract_inverted_index.suggest | 121 |
| abstract_inverted_index.testing | 17, 169 |
| abstract_inverted_index.therapy | 67, 129 |
| abstract_inverted_index.variant | 86 |
| abstract_inverted_index.(25.9%). | 118 |
| abstract_inverted_index.(80.0%). | 92 |
| abstract_inverted_index.(87.0%), | 113 |
| abstract_inverted_index.(90.7%), | 111 |
| abstract_inverted_index.Advanced | 43 |
| abstract_inverted_index.Genomics | 41 |
| abstract_inverted_index.analyzed | 28 |
| abstract_inverted_index.clinical | 149 |
| abstract_inverted_index.compared | 69 |
| abstract_inverted_index.evidence | 146 |
| abstract_inverted_index.findings | 120 |
| abstract_inverted_index.included | 97 |
| abstract_inverted_index.patients | 32, 48, 59, 177 |
| abstract_inverted_index.provides | 144 |
| abstract_inverted_index.receptor | 3 |
| abstract_inverted_index.response | 63 |
| abstract_inverted_index.revealed | 106 |
| abstract_inverted_index.standard | 56 |
| abstract_inverted_index.testing. | 57 |
| abstract_inverted_index.treating | 9 |
| abstract_inverted_index.variants | 23, 53, 96, 125, 154 |
| abstract_inverted_index.Epidermal | 0 |
| abstract_inverted_index.affecting | 24 |
| abstract_inverted_index.anti-EGFR | 34, 66, 128 |
| abstract_inverted_index.database, | 45 |
| abstract_inverted_index.efficacy. | 26 |
| abstract_inverted_index.mutations | 117 |
| abstract_inverted_index.non-V600E | 115 |
| abstract_inverted_index.potential | 133 |
| abstract_inverted_index.profiling | 105, 138 |
| abstract_inverted_index.receiving | 33 |
| abstract_inverted_index.relevance | 150 |
| abstract_inverted_index.response, | 130 |
| abstract_inverted_index.treatment | 25, 140, 156, 174 |
| abstract_inverted_index.variants. | 181 |
| abstract_inverted_index.wild-type | 11, 72, 90 |
| abstract_inverted_index.additional | 107 |
| abstract_inverted_index.antibodies | 35 |
| abstract_inverted_index.approaches | 175 |
| abstract_inverted_index.colorectal | 13, 30, 159 |
| abstract_inverted_index.developing | 166 |
| abstract_inverted_index.evaluating | 172 |
| abstract_inverted_index.inhibition | 5 |
| abstract_inverted_index.metastatic | 12 |
| abstract_inverted_index.real-world | 145 |
| abstract_inverted_index.strategies | 170 |
| abstract_inverted_index.supporting | 147 |
| abstract_inverted_index.alterations | 108 |
| abstract_inverted_index.alternative | 173 |
| abstract_inverted_index.identifying | 46 |
| abstract_inverted_index.initiation. | 141 |
| abstract_inverted_index.Therapeutics | 44 |
| abstract_inverted_index.highlighting | 131 |
| abstract_inverted_index.undetectable | 54 |
| abstract_inverted_index.A11_G12insGA. | 102 |
| abstract_inverted_index.Comprehensive | 103 |
| abstract_inverted_index.comprehensive | 136, 168 |
| abstract_inverted_index.significantly | 61 |
| abstract_inverted_index.cost-effective | 167 |
| abstract_inverted_index.decision-making | 157 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 96 |
| corresponding_author_ids | https://openalex.org/A5114928862 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 8 |
| corresponding_institution_ids | https://openalex.org/I112524849 |
| citation_normalized_percentile.value | 0.83338906 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |